News

Yahoo Finance

Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension

Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment ...
Morningstar

TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension

Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the ...
Taiwan News

Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call

Idorsia will host a live investor Q&A webcast and conference call following the publication of the OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension ...
FiercePharma

Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension

After Johnson & Johnson last year changed its mind on its 2017 purchase of aprocitentan, the medicine's original maker has ushered the drug across the FDA finish line. The once-daily drug, branded as ...
Finanznachrichten

Idorsia Pharmaceuticals Ltd: Idorsia's TRYVIO - First FDA-approved therapy to target the endothelin pathway for systemic hypertension

Allschwil, Switzerland - August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast (https://www.idorsia.com/investors) outlining how TRYVIO ...